Pacira BioSciences, Inc. (PCRX) income statement
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3034% above fair value
$36.48+0.02 (+0.05%)
Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 79.2%
- Operating margin
- 2.7%
- Net margin
- 2.0%
- Return on equity, FY2025
- 1.0%
Financial strength
- Current ratio
- 5.04
- Debt to equity
- 0.54
- Debt to assets
- 29.2%
- Cash to current liabilities
- 168.7%
Valuation
- P/E ratio
- 104.2
- Price to sales
- 1.95
- Price to book
- 2.16
- Dividend yield
- –
See a number that looks wrong?